T. Rowe Price Associates’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$1.42M Buy
122,202
+22,740
+23% +$265K ﹤0.01% 1808
2025
Q1
$740K Buy
99,462
+5,570
+6% +$41.4K ﹤0.01% 2093
2024
Q4
$563K Sell
93,892
-65,931
-41% -$395K ﹤0.01% 2232
2024
Q3
$819K Buy
159,823
+1,016
+0.6% +$5.21K ﹤0.01% 2047
2024
Q2
$575K Buy
158,807
+3,578
+2% +$13K ﹤0.01% 2135
2024
Q1
$499K Sell
155,229
-137,655
-47% -$443K ﹤0.01% 2211
2023
Q4
$1.44M Sell
292,884
-15,867
-5% -$77.8K ﹤0.01% 1695
2023
Q3
$1.68M Sell
308,751
-1,238,541
-80% -$6.75M ﹤0.01% 1536
2023
Q2
$10.4M Sell
1,547,292
-211,657
-12% -$1.42M ﹤0.01% 1074
2023
Q1
$15.5M Sell
1,758,949
-79,517
-4% -$702K ﹤0.01% 977
2022
Q4
$14M Sell
1,838,466
-53,618
-3% -$410K ﹤0.01% 992
2022
Q3
$13.5M Sell
1,892,084
-10,291,811
-84% -$73.3M ﹤0.01% 1009
2022
Q2
$98.6M Sell
12,183,895
-232,472
-2% -$1.88M 0.01% 670
2022
Q1
$172M Sell
12,416,367
-870,346
-7% -$12.1M 0.02% 571
2021
Q4
$373M Buy
13,286,713
+1,840,491
+16% +$51.6M 0.03% 405
2021
Q3
$389M Buy
11,446,222
+479,331
+4% +$16.3M 0.04% 392
2021
Q2
$448M Buy
10,966,891
+1,342,666
+14% +$54.9M 0.04% 361
2021
Q1
$387M Buy
9,624,225
+3,669,449
+62% +$148M 0.04% 383
2020
Q4
$352M Buy
5,954,776
+2,114,378
+55% +$125M 0.04% 399
2020
Q3
$187M Buy
3,840,398
+1,117,025
+41% +$54.3M 0.02% 500
2020
Q2
$132M Sell
2,723,373
-580,147
-18% -$28.1M 0.02% 564
2020
Q1
$91.8M Buy
3,303,520
+1,101,522
+50% +$30.6M 0.01% 595
2019
Q4
$65.9M Buy
2,201,998
+1,495,074
+211% +$44.7M 0.01% 805
2019
Q3
$21.8M Sell
706,924
-193,076
-21% -$5.97M ﹤0.01% 1116
2019
Q2
$43.5M Buy
+900,000
New +$43.5M 0.01% 933